Q1 2025 Ginkgo Bioworks Holdings Inc Earnings Call Transcript
Key Points
- Ginkgo Bioworks Holdings Inc (DNA) achieved a $205 million reduction in annual run rate costs, surpassing their target of $200 million.
- The company reported a 37% increase in Cell Engineering revenue for Q1 2025 compared to Q1 2024, driven by growth with biopharma and government customers.
- Ginkgo Bioworks Holdings Inc (DNA) has $517 million in cash and cash equivalents with no bank debt, positioning it strongly among peers.
- The company is expanding its market reach by offering its platform as a tools business, allowing for a broader customer base.
- Ginkgo Bioworks Holdings Inc (DNA) secured a $29 million contract with ARPA-H, enhancing revenue visibility and derisking guidance for the year.
- The company reported a negative adjusted EBITDA of $47 million for Q1 2025, although this was an improvement from the previous year.
- There is ongoing pressure in the biotech capital markets, which could impact future funding and growth opportunities.
- Revenue per program appears to be down, attributed to a mix shift from larger solutions deals to smaller data point deals.
- The tools business, while promising, is still in early stages and contributes less than 10% of cell engineering revenue.
- The company faces challenges in subleasing excess space, which remains a cash operating cost not related to driving revenue.
Good evening. I'm Daniel Marshall, Senior Manager of Communications and Ownership. It's my third year here at Ginkgo. I spent much of that time working behind the scenes with our Investor Relations team on these earnings calls, but I'm thrilled to be joining you for the first time live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks, as always, for joining us. We're looking forward to updating you on our progress.
As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K.
Today, in addition to updating you on the quarter results, we're going to provide updates on our path towards adjusted EBITDA breakeven, traction with our government clients as well as new offerings and opportunities emerging for our tools businesses.
As usual, we'll end with a Q
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
